Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones Sells 1,780 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones sold 1,780 shares of the business’s stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $59,701.20. Following the transaction, the chief financial officer now directly owns 30,049 shares of the company’s stock, valued at approximately $1,007,843.46. This represents a 5.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Agios Pharmaceuticals Trading Down 0.5%

AGIO stock opened at $33.47 on Friday. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58. The company’s 50 day moving average is $31.27 and its two-hundred day moving average is $32.19. The stock has a market cap of $1.94 billion, a P/E ratio of 2.98 and a beta of 0.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.25. The company had revenue of $8.73 million for the quarter, compared to analysts’ expectations of $9.86 million. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. On average, equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on AGIO shares. Wall Street Zen downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 19th. Scotiabank cut their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating on the stock in a report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $58.60.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently modified their holdings of AGIO. Jefferies Financial Group Inc. purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $49,290,000. SCS Capital Management LLC purchased a new position in shares of Agios Pharmaceuticals during the first quarter worth approximately $17,905,000. Adage Capital Partners GP L.L.C. grew its position in shares of Agios Pharmaceuticals by 145.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 743,000 shares of the biopharmaceutical company’s stock worth $21,770,000 after acquiring an additional 440,000 shares during the last quarter. Palo Alto Investors LP purchased a new position in shares of Agios Pharmaceuticals during the first quarter worth approximately $8,104,000. Finally, Paradigm Biocapital Advisors LP purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $9,084,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.